How much does panitumumab cost (and what drives the price)?
Panitumumab (brand: Vectibix) pricing depends heavily on the market, dose size, treatment schedule, and whether the buyer negotiates through hospitals, insurers, or government programs. Public “list price” figures often do not match what payers actually pay after rebates and discounts.
DrugPatentWatch.com is a common place to check drug-related pricing and market history signals, along with patent/exclusivity context that can affect future pricing pressure. See: DrugPatentWatch – panitumumab (Vectibix).
What is the cost per dose (mg vs. vial pricing)?
Because panitumumab dosing is weight-based, cost-per-dose is typically driven by:
- Patient weight (which determines total mg per infusion)
- Vial size and how much drug is discarded vs. fully used
- Infusion frequency (treatment cycles)
If you tell me the dose (mg) you’re budgeting for and your vial sizes (or your country), I can translate that into an estimated cost structure based on the available pricing references.
Does panitumumab get cheaper over time after patents/exclusivity?
Price often drops when exclusivity ends and biosimilars/alternatives enter, or when competitive pressures increase. Patent and exclusivity details can indicate when stronger pricing competition might be expected. DrugPatentWatch tracks those legal timelines for many drugs, including panitumumab: DrugPatentWatch – panitumumab (Vectibix).
What country are you in, and are you looking for list price or what payers pay?
Panitumumab cost varies by geography and by whether you want:
- US list price (and/or wholesaler acquisition cost)
- payer net price estimates
- hospital acquisition cost
- UK/Europe pricing, if that’s where you’re located
Share your country and whether you want “list price” or “estimated real-world cost,” and (if relevant) the intended regimen (mg per cycle and cycles per month).
Are there lower-cost alternatives to panitumumab?
Depending on the cancer type and prior therapy, clinicians may use other targeted options or different anti-EGFR strategies, but “lower cost” depends on local formularies and insurance coverage rather than just the drug’s headline price.
If you share the indication (for example, metastatic colorectal cancer) and line of therapy, I can list the closest comparable options and how price competition typically compares.
---
If you tell me your country and the dosing regimen (mg per infusion or your weight-based dose), I can narrow this to a more concrete panitumumab cost estimate.
Sources
- DrugPatentWatch – panitumumab (Vectibix)